Eculizumab as rescue therapy in severe resistant lupus nephritis

Rheumatology (United Kingdom)

Volumn 54, Issue 12, 2015, Pages 2286-2288

  Pickering, Matthew C ^a   Ismajli, Mediola ^a   Condon, Marie B ^a   McKenna, Nicola ^a   Hall, Angela E ^a   Lightstone, Liz ^a   Cook, H Terence ^a   Cairns, Thomas D ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN C; ECULIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; RITUXIMAB; COMPLEMENT COMPONENT C5; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ALOPECIA; ARTHRALGIA; CASE REPORT; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LETTER; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL HISTORY; MOUTH ULCER; PLEURISY; PRIORITY JOURNAL; THROMBOCYTOPENIC PURPURA; ANTAGONISTS AND INHIBITORS; BIOPSY; KIDNEY; LUPUS NEPHRITIS; PATHOLOGY; PROCEDURES; SALVAGE THERAPY;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY; COMPLEMENT C5; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS NEPHRITIS; SALVAGE THERAPY;

EID: 84983094382     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev307     Document Type: Letter

References (8)

1. Hillmen P, Hall C, Marsh JC et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. New Engl J Med 2004;350:552-9.
2. Condon MB, Ashby D, Pepper RJ et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013;72:1280-6.
3. Barilla-Labarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol 2013;148:313-21.
4. Wang Y, Hu Q, Madri JA et al. Amelioration of lupus-like autoimmune disease in NZB/WF 1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A 1996;93:8563-8.
5. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169-81.
6. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C 3 glomerulonephritis. Clin J Am Soc Nephrol 2012;7:748-56.
7. Coppo R, Peruzzi L, Amore A et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 2015;30:167-72.
8. Rosenblad T, Rebetz J, Johansson M et al. Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 2014;29:2225-8.